13 Publikationen in 2020
Kumulativer IF: 182.7
Mittelwert IF: 15.22

1. Cardioprotection by early metoprolol- attenuation of ischemic vs. reperfusion injury?
Kleinbongard P
Basic Res Cardiol; 115:54    (Impact Factor = 17,165)

2. Is metoprololmore cardioprotective than other beta-blockers?
Heusch G, Kleinbongard P
Eur Heart J; 41:4441-4443    (Impact Factor = 29,983)

3. Left Ventricular Unloading in Myocardial Infarction Gentle Reperfusion Through the Backdoor?
Heusch G, Rassaf T
J Am Coll Cardiol; 76:700-702    (Impact Factor = 24,093)

4. Myocardial ischaemia-reperfusion injury and cardioprotection in perspective
Heusch G
Nat Rev Cardiol; 17:773-789    (Impact Factor = 32,43)

5. Anaemia is associated with severe RBC dysfunction and a reduced circulating NO pool: vascular and cardiac eNOS are crucial for the adaptation to anaemia
Wischmann P, Kuhn V, Suvorava T, Muessig JM, Fischer JW, Isakson BE, Haberkorn SM, Flögel U, Schrader J, Jung C, Cortese-Krott MM, Heusch G, Kelm M
Basic Res Cardiol; 115:43    (Impact Factor = 17,165)

6. Is Cardioprotection Salvageable?
Heusch G, Gersh BJ
Circulation; 141:415-417    (Impact Factor = 29,69)

7. Extracellular vesicles isolated from patients undergoing remote ischemic preconditioning decrease hypoxia-evoked apoptosis of cardiomyoblasts after isoflurane but not propofol exposure
Abel F, Murke F, Gaida M, Garnier N, Ochsenfarth C, Theiss C, Thielmann M, Kleinbongard P, Giebel B, Peters J, Frey UH
PLoS One; 15:e0228948    (Impact Factor = 3,24)

8. Translational issues for mitoprotective agents as adjunct to reperfusion therapy in patients with ST-segment elevation myocardial infarction
Botker HE, Cabrera-Fuentes HA, Ruiz-Meana M, Heusch G, Ovize M
J Cell Mol Med; 24:2717-2729    (Impact Factor = 5,31)

9. Hyperlipidaemia and cardioprotection: Animal models for translational studies
Andreadou I, Schulz R, Badimon L, Adameova A, Kleinbongard P, Lecour S, Nikolaou PE, Falcao-Pires I, Vilahur G, Woudberg N, Heusch G, Ferdinandy P
Br J Pharmacol; 177:5287-5311    (Impact Factor = 8,74)

10. Co-morbidities and co-medications as confounders of cardioprotection-Does it matter in the clinical setting?
Kleinbongard P, Botker HE, Ovize M, Hausenloy DJ, Heusch G
Br J Pharmacol; 177:5252-5269    (Impact Factor = 8,74)

11. The German CPU registry: Comparison of smokers and nonsmokers
Bock D, Senges J, Pohlmann C, Hochadel M, Munzel T, Giannitsis E, Schmitt C, Heusch G, Voigtlander T, Mudra H, Schumacher B, Darius H, Maier LS, Hailer B, Haude M, Gohlke H, Hink U
Herz; 45:293-298    (Impact Factor = 1,443)

12. Guideline-adherence regarding critical time intervals in the German Chest Pain Unit registry
Vafaie M, Hochadel M, Muenzel T, Hailer B, Schumacher B, Heusch G, Voigtlaender T, Mudra H, Haude M, Barth S, Schmitt C, Darius H, Maier LS, Katus HA, Senges J, Giannitsis E
Eur Heart J-Acute Cardiovasc Care; 9:52-61    (Impact Factor = 4,696)

13. Takotsubo syndrome
Möhlenkamp S, Kleinbongard P, Erbel R
Kardiologe; 14:323-336    (Impact Factor = )